AN2 Therapeutics (ANTX) Shares Outstanding (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Shares Outstanding data on file, last reported at $36.0 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $36.0 million, up 19.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.0 million (up 19.39% YoY), and the FY2025 annual result was $27.4 million, down 8.38% from the prior year.
• Shares Outstanding advanced to $36.0 million in Q1 2026 per ANTX's latest filing, from $27.4 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $36.0 million in Q1 2026 and troughed at $18.7 million in Q1 2022.
• A 5-year average of $26.2 million and a median of $27.4 million in 2025 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding soared 610.64% in 2022, then dropped 8.38% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $19.4 million in 2022, then surged by 53.29% to $29.7 million in 2023, then advanced by 0.6% to $29.9 million in 2024, then dropped by 8.38% to $27.4 million in 2025, then surged by 31.27% to $36.0 million in 2026.
• Business Quant data shows ANTX's Shares Outstanding at $36.0 million in Q1 2026, $27.4 million in Q4 2025, and $27.4 million in Q3 2025.